NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VRAX
Virax Biolabs Group Limited
There isn't enough reported data to score VRAX yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
VRAX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate VRAX's fundamentals.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
VRAX PE Valuation
VRAX has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
VRAX Forward outlook
There aren't enough analyst estimates for VRAX to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
VRAX Earnings Per Share
VRAX and NVO do not have enough comparable growth data to identify a winner.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over VRAX in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over VRAX on profitability, with a higher operating margin.
VRAX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $12.4K | +802% |
| Q3 2025 | $1.6K | -68% |
| Q1 2025 | $1.4K | -98% |
| Q3 2024 | $5K | -94% |
| Q1 2024 | $79.9K | +2753% |
| Q3 2023 | $76.5K | +1228% |
| Q1 2021 | $109.8K | +340% |
| Q3 2020 | $14K | -81% |
VRAX's revenue has slid since its 2021 peak: $12,423 last quarter, down 84% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -51515% | -46773 points |
| Q3 2025 | -160788% | -157251 points |
| Q1 2025 | -238317% | -85079 points |
| Q3 2024 | -58124% | -33114 points |
| Q1 2024 | -4743% | N/A |
| Q3 2023 | -3538% | N/A |
| Q1 2023 | -153238% | -152989 points |
| Q3 2022 | -25010% | -22357 points |
VRAX's operating margin was −51515% last quarter, down 46773 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
VRAX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.9M | -$1.9M |
| Q3 2025 | -$3.1M | -$898.3K |
| Q1 2025 | -$3M | +$248.4K |
| Q3 2024 | -$2.2M | +$2M |
| Q1 2024 | -$3.2M | -$1.2M |
| Q3 2023 | -$4.2M | -$1.9M |
| Q1 2023 | -$2.1M | -$1.5M |
| Q3 2022 | -$2.3M | -$2M |
VRAX has burned cash in almost every quarter: −$13M over the past year, against −$12M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over VRAX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
VRAX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.3% | +16.2K shares |
| 1 year | +168% | +120K shares |
VRAX has 190,520 diluted shares, up 168% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q3 2025 | — |
| Q1 2025 | — |
| Q3 2024 | — |
| Q1 2024 | $85,500 |
| Q3 2023 | — |
| Q1 2023 | — |
| Q3 2022 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
VRAX Net Leverage
VRAX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
VRAX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.5 | Oversold |
| Stochastic | 3.7 | Oversold |
VRAX's weekly RSI is 29 (oversold) and its Stochastic is 4 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VRAX PE vs Healthcare Sector
VRAX has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over VRAX on trend strength, trading above more of its moving averages.
VRAX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.48 | 55% below |
| 20 week MA | $2.42 | 72% below |
| 50 week MA | $4.59 | 85% below |
| 100 week MA | $15.9 | 96% below |
| 200 week MA | $44.9 | 99% below |
VRAX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over VRAX on returns for 2026, with the stronger performance.
VRAX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $2,585.0 | $142.5 | -94% |
| 2023 | $142.5 | $36.5 | -74% |
| 2024 | $36.5 | $52.5 | +44% |
| 2025 | $52.5 | $8.98 | -83% |
| 2026 YTD | $8.98 | $0.67 | -93% |
VRAX has finished lower in three of the last four years. It's down 93% so far in 2026.